Dr Reddys Laboratories Ltd 6-K, filed Feb 22, 2022
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on February 22, 2022.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February, 2022
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
| Exhibit Number |
Description of Exhibits | |
| 99.1 | Press Release dated February 21, 2022 | |
| 99.2 | Intimation dated February 21, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||
| Date: February 21, 2022 | By: | /s/ Vivek Mittal | |
| Name: | Vivek Mittal | ||
| Title: | Global General Counsel and Compliance Officer | ||
Exhibit 99.1
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
February 21, 2022
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | “Exchange Plaza” |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai – 400 001 | Mumbai – 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Press Release
Please find enclosed a Press Release on “Binnopharm Group enters into agreement to acquire two anti-bacterial brands from Dr. Reddy’s in the Russia & CIS region”
This is for your information.
With regards,
| /s/ Vivek Mittal | |
| Vivek Mittal | |
| Global General Counsel and Compliance Officer |
Encl: As above
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
NSE IFSC Ltd.
 |
 |
Binnopharm Group enters into agreement to acquire
two anti-bacterial
brands from Dr. Reddy’s in the Russia & CIS region
| · | Through its affiliate Joint Stock Company, Alium, Binnopharm Group will acquire the two anti-bacterial brands Ciprolet® and Levolet® in Russia, Belarus and Uzbekistan to strengthen its antibiotic portfolio |
| · | For Dr. Reddy’s, this divestment of brands from its non-core areas will allow the company to focus its resources and capabilities on its key therapy spaces of gastro-enterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company |
Moscow, Russia and Hyderabad India; February 21, 2022: The Sistema Group company (LSE: SSA, MOEX: AFKS), Binnopharm Group, one of the leading pharmaceutical production companies in Russia via its affiliate Joint Stock Company ‘Alium’, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), an integrated global pharmaceutical company, today announced the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet® and Levolet® brands from Dr. Reddy’s in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.
Rustem Muratov, CEO of the Binnopharm Group said: “The acquisition of Ciprolet® and Levolet® is an important step to enhance our position in the antibiotics market, one of the key market segments for Binnopharm Group. These strong brands have already had the trust of millions of consumers – according to independent analyst estimation they are leaders in their market segments. They will be a valuable complement to our portfolio of antibacterial products. We are also acquiring rights to these products in Belarus and Uzbekistan in line with our strategic goal to strengthen presence in the international markets.”
M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), said: “Our Russia and CIS markets continue to be strong performers for the company. This deal is a step towards divesting brands in non-core areas in order to consolidate and strengthen our play further in our key focus therapy areas of gastro-enterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health. This will help us accelerate access to affordable and innovative medicines in the region in these segments in keeping with our purpose of ‘Good Health Can’t Wait’.”
| |
|
During the transition period, Dr. Reddy’s will continue to supply the product to Binnopharm Group to ensure availability in the market.
About Binnopharm Group
Binnopharm Group was founded in 2020 through consolidation of pharmaceutical assets of Sistema PJSFC., Binnopharm Group is Russia’s largest producer of antibiotics and the No. 1 manufacturer of products intended for CIS exports, a Top 3 Russian pharmaceutical company (according to AlphaRM). The company has 5 production assets in different Russian regions. The assets manufacture a total of 200+ pharmacological groups in various dosage forms (from tablets and capsules to ointments, gels, suppositories, infusion solutions, etc.) and boast one of the largest portfolios among Russian manufacturers – 450+ marketing authorisations. For more information, log on to: https://en.binnopharmgroup.ru.
Contact information for Binnopharm Group:
| Investor Relations | Media Relations |
| Nikolay Minashin | Elena Shipilova |
| nminashin@binnopharmgroup.ru | eshipilova@binnopharmgroup.ru |
About Dr. Reddy's Laboratories:
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Contact information for Dr. Reddy’s:
| Investor Relations | Media Relations |
| Amit Agarwal | Usha Iyer |
| amita@drreddys.com | ushaiyer@drreddys.com |
Exhibit 99.2
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
February 21, 2022
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | “Exchange Plaza” |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai – 400 001 | Mumbai – 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Intimation
Further to our intimation dated October 29, 2021, on the audit conducted by the USFDA at our formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection.
This is for your information.
With regards,
| /s/ Vivek Mittal | |
| Vivek Mittal | |
| Global General Counsel and Compliance Officer |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
NSE IFSC Ltd.